# A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Source: https://onco.cc/trials/nct06157892/  
OnCo record `nct06157892` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin and Tucatinib in gastric & gastro-oesophageal junction cancer, HER2-positive breast cancer and triple-negative breast cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.

## Summary

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors is a phase 2 interventional study registered as NCT06157892 by Seagen, a wholly owned subsidiary of Pfizer, with 54 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2029-07-28. Interventions recorded: disitamab vedotin and tucatinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06157892
- Phase: 2
- Setting: A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT06157892: https://clinicaltrials.gov/study/NCT06157892

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Tucatinib](https://onco.cc/drugs/tucatinib/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06157892.json